메뉴 건너뛰기




Volumn 7, Issue 9, 2017, Pages

Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: Protocol for a systematic review and meta-analysis

(18)  Khan, Faizan a,b   Rahman, Alvi a   Carrier, Marc a,b,c   Kearon, Clive d   Schulman, Sam d   Couturaud, Francis e   Prandoni, Paolo f   Eichinger, Sabine g   Becattini, Cecilia h   Agnelli, Giancarlo h   Büller, Harry R i   Brighton, Timothy A j   Palareti, Gualtiero k   Pinede, Laurent l   Sabri, Elham b   Hutton, Brian a,b   Wells, George A a,m   Rodger, Marc A a,b,c  


Author keywords

anticaogulants; recurrence; venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN;

EID: 85029887047     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2017-016950     Document Type: Article
Times cited : (7)

References (34)
  • 1
    • 85003443860 scopus 로고    scopus 로고
    • Deep vein thrombosis and pulmonary embolism
    • Di Nisio M, van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. Lancet 2016;388:3060-73.
    • (2016) Lancet , vol.388 , pp. 3060-3073
    • Di Nisio, M.1    Van Es, N.2    Büller, H.R.3
  • 2
    • 84938198885 scopus 로고    scopus 로고
    • Epidemiology of venous thromboembolism
    • Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015;12:464-74.
    • (2015) Nat Rev Cardiol , vol.12 , pp. 464-474
    • Heit, J.A.1
  • 3
    • 84958038787 scopus 로고    scopus 로고
    • Antithrombotic therapy for vte disease: Chest guideline and expert panel report
    • Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016;149:315-52.
    • (2016) Chest , vol.149 , pp. 315-352
    • Kearon, C.1    Akl, E.A.2    Ornelas, J.3
  • 4
    • 84897509629 scopus 로고    scopus 로고
    • Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism
    • Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood 2014;123:1794-801.
    • (2014) Blood , vol.123 , pp. 1794-1801
    • Kearon, C.1    Akl, E.A.2
  • 5
    • 77952524191 scopus 로고    scopus 로고
    • Systematic review: Case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism
    • Carrier M, Le Gal G, Wells PS, et al. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann intern med 2010;152:578-89.
    • (2010) Ann Intern Med , vol.152 , pp. 578-589
    • Carrier, M.1    Le Gal, G.2    Wells, P.S.3
  • 6
    • 84884548759 scopus 로고    scopus 로고
    • Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: Systematic review and network meta-Analysis
    • Castellucci LA, Cameron C, Le Gal G, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-Analysis. BMJ 2013;347:f5133.
    • (2013) BMJ , vol.347 , pp. f5133
    • Castellucci, L.A.1    Cameron, C.2    Le Gal, G.3
  • 7
    • 84859000239 scopus 로고    scopus 로고
    • Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: Analysis of individual participants' data from seven trials
    • Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ 2011;342:d3036.
    • (2011) BMJ , vol.342 , pp. d3036
    • Boutitie, F.1    Pinede, L.2    Schulman, S.3
  • 8
    • 77955427593 scopus 로고    scopus 로고
    • Unprovoked venous thromboembolism: Short term or indefinite anticoagulation? Balancing long-term risk and benefit
    • Rodger M, Carrier M, Gandara E, et al. Unprovoked venous thromboembolism: short term or indefinite anticoagulation? balancing long-term risk and benefit. Blood rev 2010;24:171-8.
    • (2010) Blood Rev , vol.24 , pp. 171-178
    • Rodger, M.1    Carrier, M.2    Gandara, E.3
  • 9
    • 84937207208 scopus 로고    scopus 로고
    • Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: The padis-pe randomized clinical trial
    • Couturaud F, Sanchez O, Pernod G, et al. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: The PADIS-PE randomized clinical trial. JAMA 2015;314:31-40.
    • (2015) JAMA , vol.314 , pp. 31-40
    • Couturaud, F.1    Sanchez, O.2    Pernod, G.3
  • 10
    • 84911864852 scopus 로고    scopus 로고
    • 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism
    • Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014;35:3033-69.
    • (2014) Eur Heart J , vol.35 , pp. 3033-3069
    • Konstantinides, S.V.1    Torbicki, A.2    Agnelli, G.3
  • 11
    • 84964318237 scopus 로고    scopus 로고
    • Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: A multi-national cohort
    • Rodger MA, Scarvelis D, Kahn SR, et al. Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: a multi-national cohort. Thromb res 2016;143:152-8.
    • (2016) Thromb Res , vol.143 , pp. 152-158
    • Rodger, M.A.1    Scarvelis, D.2    Kahn, S.R.3
  • 12
    • 85003888960 scopus 로고    scopus 로고
    • The long-term recurrence risk of patients with unprovoked venous thromboembolism: An observational cohort study
    • Kyrle PA, Kammer M, Eischer L, et al. The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study. J thromb haemost 2016;14:2402-9.
    • (2016) J Thromb Haemost , vol.14 , pp. 2402-2409
    • Kyrle, P.A.1    Kammer, M.2    Eischer, L.3
  • 13
    • 78649359714 scopus 로고    scopus 로고
    • Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: Recommendation for acceptable rates and standardized reporting
    • Kearon C, Iorio A, Palareti G. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. J Thromb Haemost 2010;8:2313-5.
    • (2010) J Thromb Haemost , vol.8 , pp. 2313-2315
    • Kearon, C.1    Iorio, A.2    Palareti, G.3
  • 14
    • 79952255467 scopus 로고    scopus 로고
    • Risk of recurrence after venous thromboembolism in men and women: Patient level metaanalysis
    • Douketis J, Tosetto A, Marcucci M, et al. Risk of recurrence after venous thromboembolism in men and women: patient level metaanalysis. BMJ 2011;342:d813.
    • (2011) BMJ , vol.342 , pp. d813
    • Douketis, J.1    Tosetto, A.2    Marcucci, M.3
  • 15
    • 53749084691 scopus 로고    scopus 로고
    • Systematic review: D-dimer to predict re-current disease after stopping anticoagulant therapy for unprovoked venous thromboembolism
    • Verhovsek M, Douketis JD, Yi Q, et al. Systematic review: D-dimer to predict re-current disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann intern med 2008;149:481-90.
    • (2008) Ann Intern Med , vol.149 , pp. 481-490
    • Verhovsek, M.1    Douketis, J.D.2    Yi, Q.3
  • 16
    • 77950920123 scopus 로고    scopus 로고
    • Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: The vienna prediction model
    • Eichinger S, Heinze G, Jandeck LM, et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010;121:1630-6.
    • (2010) Circulation , vol.121 , pp. 1630-1636
    • Eichinger, S.1    Heinze, G.2    Jandeck, L.M.3
  • 17
    • 84861684787 scopus 로고    scopus 로고
    • Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: A proposed prediction score (dash
    • Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J thromb haemost 2012;10:1019-25.
    • (2012) J Thromb Haemost , vol.10 , pp. 1019-1025
    • Tosetto, A.1    Iorio, A.2    Marcucci, M.3
  • 18
    • 50649107286 scopus 로고    scopus 로고
    • Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy
    • Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008;179:417-26.
    • (2008) CMAJ , vol.179 , pp. 417-426
    • Rodger, M.A.1    Kahn, S.R.2    Wells, P.S.3
  • 19
    • 85015779142 scopus 로고    scopus 로고
    • Validating the herdoo2 rule to guide treatment duration for women with unprovoked venous thrombosis: Multinational prospective cohort management study
    • Rodger MA, Le Gal G, Anderson DR, et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ 2017;356:j1065.
    • (2017) BMJ , vol.356 , pp. j1065
    • Rodger, M.A.1    Le Gal, G.2    Anderson, D.R.3
  • 20
    • 84990179336 scopus 로고    scopus 로고
    • Categorization of patients as having provoked or unprovoked venous thromboembolism: Guidance from the ssc of isth
    • Kearon C, Ageno W, Cannegieter SC, et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 2016;14:1480-3.
    • (2016) J Thromb Haemost , vol.14 , pp. 1480-1483
    • Kearon, C.1    Ageno, W.2    Cannegieter, S.C.3
  • 21
    • 85040810898 scopus 로고    scopus 로고
    • AnnArborMichigan USA: ProQuest LLC
    • RefWorks. AnnArbor,Michigan, USA: ProQuest LLC, 2016.
    • (2016) RefWorks
  • 22
    • 85019181548 scopus 로고    scopus 로고
    • Covidence. Victoria Australia
    • Covidence. Covidence. Victoria, Australia, 2015.
    • (2015) Covidence
  • 23
    • 68049122102 scopus 로고    scopus 로고
    • Preferred reporting items for systematic reviews and meta-Analyses: The prisma statement
    • Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. PLoS med 2009;6:e1000097.
    • (2009) PLoS Med , vol.6 , pp. e1000097
    • Moher, D.1    Liberati, A.2    Tetzlaff, J.3
  • 24
    • 84859001212 scopus 로고    scopus 로고
    • The cochrane collaboration's tool for assessing risk of bias in randomised trials
    • Higgins JP, Altman DG, Gøtzsche PC, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
    • (2011) BMJ , vol.343 , pp. d5928
    • Higgins, J.P.1    Altman, D.G.2    Gøtzsche, P.C.3
  • 26
    • 80053351531 scopus 로고    scopus 로고
    • Conducting quantitative synthesis when comparing medical interventions: Ahrq and the effective health care program
    • Fu R, Gartlehner G, Grant M, et al. Conducting quantitative synthesis when comparing medical interventions: ahrq and the effective health care program. J clin epidemiol 2011;64:1187-97.
    • (2011) J Clin Epidemiol , vol.64 , pp. 1187-1197
    • Fu, R.1    Gartlehner, G.2    Grant, M.3
  • 28
    • 84921536011 scopus 로고    scopus 로고
    • Aspirin for the prevention of recurrent venous thromboembolism: The inspire collaboration
    • Simes J, Becattini C, Agnelli G, et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation 2014;130:1062-71.
    • (2014) Circulation , vol.130 , pp. 1062-1071
    • Simes, J.1    Becattini, C.2    Agnelli, G.3
  • 29
    • 79951955198 scopus 로고    scopus 로고
    • Grade guidelines 3. Rating the quality of evidence
    • Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J clin epidemiol 2011;64:401-6.
    • (2011) J Clin Epidemiol , vol.64 , pp. 401-406
    • Balshem, H.1    Helfand, M.2    Schünemann, H.J.3
  • 31
    • 23044505564 scopus 로고    scopus 로고
    • Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
    • Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4.
    • (2005) J Thromb Haemost , vol.3 , pp. 692-694
    • Schulman, S.1    Kearon, C.2
  • 32
    • 84920780781 scopus 로고    scopus 로고
    • Preferredreporting items for systematic review and meta-Analysis protocols (prisma-p 2015 statement
    • Moher D, Shamseer L, Clarke M, et al. Preferredreporting items for systematic review and meta-Analysis protocols (PRISMA-P) 2015 statement. Syst rev 2015;4:11.
    • (2015) Syst Rev , vol.4 , pp. 11
    • Moher, D.1    Shamseer, L.2    Clarke, M.3
  • 33
    • 84920843179 scopus 로고    scopus 로고
    • Preferred reporting items for systematic review and meta-Analysis protocols (prisma-p 2015 elaboration and explanation
    • Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-Analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.
    • (2015) BMJ , vol.349 , pp. g7647
    • Shamseer, L.1    Moher, D.2    Clarke, M.3
  • 34
    • 33847606952 scopus 로고    scopus 로고
    • Development of amstar: A measurement tool to assess the methodological quality of systematic reviews
    • Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC med res methodol 2007;7:10.
    • (2007) BMC Med Res Methodol , vol.7 , pp. 10
    • Shea, B.J.1    Grimshaw, J.M.2    Wells, G.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.